Trillium Therapeutics (formerly StemCell Therapeutics, but now repurposed after that outfit crashed after a failure in stroke a few years ago) is a Canadian microcap with interesting immuno-oncology programs, in particular the anti-CD47 program. This is a hot field. The company acquired much of its pipe through an acquisition of Trillium Therapeutics in April of 2013. They have in turn licensed it from Toronto researchers. Everything is preclinical or Phase 1 at this point. Thanks to a recent reverse split, it is no longer a penny stock, but could still be subject to a) nasty financing deals, and b) slow movement in certain programs.
The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.
The website doesn't provide much in the way of links to publications or IP, so we'll have to do that digging on our own.
Website: Trillium Therapeutics |
